Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Data from a 2025 Government Accountability Office (GAO) report on TRICARE pharmacy access: The variation reflects differences in: Regional medical director interpretation of clinical criteria Local provider familiarity with GLP-1 agonist prescribing Documentation quality in prior authorization submissions Contractor staffing levels and review processes The approval rate for tirzepatide specifically (as opposed to all GLP-1 agonists) is not separately reported, but informal surveys of military endocrinologists suggest tirzepatide approval rates are 5 to 10 percentage points lower than semaglutide approval rates, likely because tirzepatide is newer and more expensive
Moderate weights with higher repetitions (8-12 reps) work well during caloric deficit, as energy for maximum strength work may be limited
Many patients dont realize these medications are FDA-approved for preventing heart disease
Medicaid Spending on GLP-1 Drugs by State Nationally, Medicaid spending on GLP-1s totaled $3.5 billion between November 2023 and October 2024, averaging $48 per Medicaid enrollee
Rare, Serious Side Effects Semaglutide's FDA label warns of a small number of rare but potentially serious side effects
